Status and phase
Conditions
Treatments
About
It is designed for Multi-center, double-masked, randomized, placebo- control study with dose escalation phase I trial to evaluate the safety, tolerability, PK and immunogenicity profiles of a single intravenous injection of IBI311 in healthy volunteers.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
28 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Huifang Zhou, Ph D.; Yongfang Yuan, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal